Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

3.21USD
24 Apr 2017
Change (% chg)

$-0.43 (-11.81%)
Prev Close
$3.64
Open
$3.70
Day's High
$3.74
Day's Low
$3.15
Volume
811,633
Avg. Vol
374,656
52-wk High
$10.06
52-wk Low
$3.15

Latest Key Developments (Source: Significant Developments)

Achillion announces initiation of patient dosing in phase 2 study of ACH-4471
Thursday, 6 Apr 2017 06:05am EDT 

Achillion Pharmaceuticals Inc : Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria . Achillion Pharmaceuticals Inc - interim results from phase 2 open-label study of ACH-4471 are anticipated during q2 of 2017 .Achillion - look forward to evaluating ACH-4471 in phase 2 trial for patients with C3 glomerulopathy that co plans initiate during H2 of this year.  Full Article

Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million
Thursday, 23 Feb 2017 05:26pm EST 

Achillion Pharmaceuticals Inc :Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million - SEC filing.  Full Article

Achillion Pharmaceuticals Q4 revenue $15 million
Thursday, 23 Feb 2017 04:05pm EST 

Achillion Pharmaceuticals Inc : Achillion reports 2016 fourth quarter and year-end financial results . Sees FY 2017 loss per share $0.70 to $0.75 . Q4 revenue $15 million . Q4 revenue view $0 -- Thomson Reuters I/B/E/S . Expects that research and development expenses during 2017 will be approximately $75 - 80 million . Net cash used in operating activities in 2017 will be approximately $70 - 75 million .FY2017 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.  Full Article

Achillion Pharmaceuticals reports Q2 loss per share $0.14
Thursday, 4 Aug 2016 04:05pm EDT 

Achillion Pharmaceuticals Inc : Achillion reports second quarter 2016 financial results .Achillion Pharmaceuticals Inc qtrly loss per share $0.14.  Full Article

Achillion presents interim phase 1 results for ACH-4471
Friday, 10 Jun 2016 03:30am EDT 

Achillion says : Presents interim phase 1 results for ACH-4471, a novel orally-administered factor D inhibitor . Results indicate up to 100% inhibition of alternative-pathway activity in hemolysis and Wieslab assays after oral dosing of ACH-447 .Results support initiation of phase 1 trial during q2 and phase 2 studies for PNH and C3G by year-end 2016.  Full Article

Achillion Pharmaceuticals Inc reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Thursday, 5 Nov 2015 04:05pm EST 

Achillion Pharmaceuticals Inc:Expects FY 2015 total annual revenue to be $66 million, representing the total premium paid by JJDC associated with its equity purchase of Achillion common stock.Expects FY 2015 net loss per share to be approximately $0.08 - 0.10 per share.FY 2015 EPS of $(0.28) - Thomson Reuters I/B/E/S.  Full Article

Achillion Pharmaceuticals Inc reports 100% svr12 from second cohort of patients
Thursday, 17 Sep 2015 06:05am EDT 

Achillion Pharmaceuticals Inc:Reports 100% svr12 from second cohort of patients in the previously-completed six week phase 2 trial evaluating odalasvir (ach-3102) and sofosbuvir for genotype 1 hcv.Says 100% svr12 reported for all patients treated for six- (n=18) or eight-weeks.Odalasvir,sofosbuvir well tolerated with no significant adverse events, ecg findings, or lab abnormalities observed during treatment.Says announced additional interim results from a phase 2 study evaluating odalasvir (also known as ach-3102).  Full Article

Achillion Pharmaceuticals Inc gives FY 2015 guidance
Monday, 10 Aug 2015 06:05am EDT 

Achillion Pharmaceuticals Inc:Sees FY 2015 revenue to be $66 million.Sees FY 2015 net loss per share to be about $0.15 per share.  Full Article

More From Around the Web

BRIEF-Achillion announces initiation of patient dosing in phase 2 study of ACH-4471

* Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria